A A A

Technology & Screenings

Diseases

Our Expertise

Treatments

With over 30 years’ experience in Ophthalmology and a focus on Medical and Surgical Retina, including Macular Degeneration, Diabetic Retinopathy, Vitreous Floaters, Cataracts, Retinal Laser, R&D New Therapies, Surgical Technology, Advanced Imaging & Clinical Studies, Professor Stanga is committed to advancing the realm of eye care and is dedicated to transforming lives through pioneering work in Ophthalmology.

In a relentless pursuit of excellence and with the aim of delivering personalised and bespoke eye care, after leaving the NHS in 2019 following a 21 years’ experience, Professor Stanga founded The Retina Clinic London, the UK’s first independent and self-contained with fully equipped on-site operating theatre retina clinic with on-site academic and research activities, including participation in industry sponsored clinical trials. These initiatives are dedicated to pushing the boundaries of eye care, fostering innovation, developing new diagnostic and treatment techniques for the betterment of patients and very importantly, providing patient choice outside of the NHS not only in terms of clinical care but also of access to clinical trials.

His contributions extend to having set up an independent Clinical & Research Fellowship Program at The Retina Clinic London.

His contributions extend to having set up an independent Clinical & Research Fellowship Program at The Retina Clinic London.

  • Prof. Stanga introduced Optical Coherence Tomography (OCT) into the clinical setting in the UK (1998), Pascal® Laser (EU, 2006), pioneered Ultra-Widefield Imaging (Intl., 2006), and introduced Swept-Source OCT (EU, 2012), Widefield SS OCT (Intl. 2019) as well as Simultaneous Ultra Widefield FFA and Navigated Peripheral OCT (Intl. 2022).
  • Developed the new Hypersonic Vitrectomy technology for Bausch and Lomb Health from Lab Bench (2012) to FDA 510(k) Clearance, First-in-Human (2017) and EU Introduction (2018).
  • Former Principal Investigator (PI) and Surgeon in a Gene Therapy Study in RP (RPGR); results published in Nature Medicine (2020).
  • First-Ever Gene Therapy surgery in the UK in the Independent Sector as part of a clinical study in Geographic Atrophy in Dry AMD (2020).
  • First UK Diabetic Eye and Age-Related Macular Degeneration Private Screening Services (Set up & Directs 2021).
  • First commercial intravitreal injection of Vabysmo® (Faricimab) in Exudative AMD outside the U.S. (2022).
  • Pioneering Multiwavelength (since 2006) and OCT Imaging of the Vitreous (since 2012) and YAG Laser Vitreolysis for the treatment of Vitreous Floaters (since 2018).
  • First utilisation in the UK of Artificial Intelligence applied to retinal imaging in the Independent Sector in everyday clinical practice (2024) 
  • First-Ever Gene Therapy surgery in the UK as part of a clinical study in Wet AMD (2024)

Prof. Stanga’s Specialities:

Prof. Stanga’s Qualifications

Professional Memberships

Prof. Stanga is Fully Registered Medical Practitioner with Specialist Registration, GMC, UK

GMC Reference No 4759748